Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
195 Clinical Trials near Allen, TX
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerSAR443765 for Asthma
Plano, Texas
This trial tests an injectable medication called SC lunsekimig in adults aged 18 to 80 with moderate-to-severe asthma. The medication aims to reduce lung inflammation and open airways, helping patients breathe more easily.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:COPD, Smoking, Tuberculosis, Others
Must Be Taking:ICS Therapy
685 Participants Needed
mRNA Vaccine for Respiratory Syncytial Virus
Plano, Texas
This trial is testing a new vaccine called mRNA-1345 to protect young children and high-risk older children from RSV. The vaccine works by teaching the immune system to recognize and fight the virus. mRNA-1345 is among the most promising RSV vaccines, leveraging the success of mRNA technology seen in COVID-19 vaccines.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 17
Key Eligibility Criteria
Disqualifiers:Acute Illness, Recent Vaccines, Others
Must Not Be Taking:Immunosuppressants, RSV Antibodies
346 Participants Needed
INS018_055 for Idiopathic Pulmonary Fibrosis
McKinney, Texas
This trial tests a new oral medication, INS018_055, in adults with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the medication is safe and well-tolerated over a few months.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40+
Key Eligibility Criteria
Disqualifiers:Acute IPF Exacerbation, Smoking, Pregnancy, Others
Must Be Taking:Antifibrotics
40 Participants Needed
EDP-938 for Respiratory Syncytial Virus
McKinney, Texas
This trial tests an oral medication called EDP-938 for adults with RSV who are at high risk of severe illness. The goal is to help fight the virus or reduce its impact.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:COPD, HIV, Hepatitis, Others
Must Not Be Taking:Antivirals, Antibacterials
180 Participants Needed
Emraclidine for Schizophrenia
Plano, Texas
This trial aims to evaluate the safety and tolerability of a medication called emraclidine, taken by mouth, in adults with schizophrenia.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Substance Use Disorder, Cardiovascular, Diabetes, Others
Must Be Taking:Antipsychotics
850 Participants Needed
Atuliflapon for Uncontrolled Asthma
McKinney, Texas
This trial is testing Atuliflapon, a new medication, in adults with moderate to severe uncontrolled asthma. It aims to see if Atuliflapon can better manage asthma symptoms for those who do not respond well to current treatments.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:COVID-19, Pulmonary Disease, Cardiac Disease, Others
Must Be Taking:Inhaled Corticosteroids, Long-acting Β2-agonists
622 Participants Needed
Afimetoran for Lupus
Allen, Texas
This trial is testing a new medication called Afimetoran to help people with active Systemic Lupus Erythematosus (SLE). The goal is to see if it can safely reduce symptoms by calming down the immune system. The study will also provide data on its effectiveness and safety over time.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Severe Lupus Nephritis, Neuropsychiatric Lupus, Mixed Connective Tissue Disease, Antiphospholipid Syndrome
268 Participants Needed
This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of lenalidomide-based therapy.
This trial will test the hypothesis for Cohort A that the proportion of patients will have an Overall Response Rate (ORR) of \> 30 % to reveal that Pomalidomide is efficacious in pretreated patients who are refractory to lenalidomide.
This trial will test the hypothesis for Cohort B that the proportion of patients will have an Overall Response Rate (ORR) of \> 70 % to reveal that POM+DARA+LD-Dex is efficacious in pretreated patients who are refractory to lenalidomide.
This trial will test the hypothesis for Cohort C that the proportion of patients will have an Overall Response Rate (ORR) of \>60% to reveal that POM+DARA+LD-Dex is efficacious in pretreated patients who are refractory to lenalidomide. This treatment will be in only Japanese patients.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Severe Renal Impairment, Heart Failure, HIV, Others
Must Not Be Taking:Pomalidomide, Daratumumab
186 Participants Needed
Trastuzumab Emtansine Safety for Cancer
Plano, Texas
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Severe Neuropathy, Heart Failure, Others
Must Be Taking:Trastuzumab Emtansine
720 Participants Needed
Zasocitinib for Vitiligo
Plano, Texas
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches).
The main aim of this study is to learn how safe zasocitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo.
The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months.
During the study, participants will visit their study clinic 11 times.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Segmental Vitiligo, Active TB, Hepatitis, HIV, Others
Must Not Be Taking:Immunosuppressants, Phototherapy
200 Participants Needed
BI 1584862 for Age-Related Macular Degeneration
Plano, Texas
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose.
This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group.
Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+
Key Eligibility Criteria
Disqualifiers:Exudative AMD, Uncontrolled Glaucoma, Others
Must Not Be Taking:IVT Treatments, Investigational Oral
138 Participants Needed
UTI Vaccine for Urinary Tract Infections
Plano, Texas
The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Immunodeficient, Neurological Disorders, Others
Must Not Be Taking:Antibiotics, Methenamine, D-mannose
448 Participants Needed
Combination Vaccine for Flu and COVID-19
Plano, Texas
This study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Pregnancy, Immunodeficiency, Cancer, Others
Must Not Be Taking:Immune-modifying Drugs, Others
107 Participants Needed
Disitamab Vedotin for Breast Cancer
Plano, Texas
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer).
This study is seeking participants who:
* have breast cancer that is hard to treat and has spread in the body (advanced cancer)
* have tumors that have HER2 on them
* have received previous treatment for their advanced breast cancer
All participants in this study will receive disitamab vedotin at the study clinic once every 2 weeks as an intravenous (IV) infusion (given directly into a vein).
Participants will take the study medicine until they or their doctor decides to stop. This might be because their cancer is getting worse, the study medicine is no longer helping, they have bad side effects, or they wish to stop taking the study medicine. During this time, the participants will have study visits every 2 weeks. After the participants have stopped taking the study medicine, they will have follow-up visits about every 6 weeks unless their cancer gets worse. After that, they will have follow-up phone calls about every 12 weeks.
The study team will look at the experiences of people receiving the study medicine. This will help the study team decide if the study medicine is safe and effective.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Metastasis, Recent Malignancy, Others
Must Be Taking:Trastuzumab, Pertuzumab, Taxane, Others
100 Participants Needed
Sibeprenlimab for Sjögren's Syndrome
Allen, Texas
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Uncontrolled Diabetes, Malignancy, Others
Must Be Taking:Hydroxychloroquine, Methotrexate
80 Participants Needed
Why Other Patients Applied
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
Know someone looking for new options?
Spread the word